• Editor-in-Chief：ZHAO Yun
  ISSN：1674-7666
  CN：31-2035/Q
  Vol.48 No.1 (1 2026)
• A Key Magazine of China Technology
  A Core Journal in Chinese Science Citation Database (CSCD)
  A Journal Included in the Chemical Abstracts (CA)
  A Journal Included in Japan Science and Technology Agency (JST)

PERSPECTIVES

Cell and Gene Therapy: Research Progress and Future Directions
[2-19]

Progress in Regulatory Science for Cell and Gene Therapy Products Domestically and Internationally
[20-32]

Global Governance of Cell and Gene Therapy and China’s Institutional Transformation
[33-50]

NEW ADVANCES

Advances in Immune Cell Therapy
[51-65]

Research Progress of Mesenchymal Stem/Stromal Cell Therapy Medicinal Product
[66-77]

Discussion on the Druggability of Hematopoietic Stem Cells
[78-98]

Advances in Pluripotent Stem Cell-Based Cell Therapies
[99-115]

Advances in the Druggability and Clinical Translation of Platelets
[116-128]

Extracellular Vesicles as Therapeutic Agents: Progress and Challenges in Translational Research
[129-145]

Progress and Future Trends in Quality Control of Gene Therapy Products
[146-165]

GMP-Grade Plasmid Production and Quality Control: a Standardized Approach from Basic Research to Clinical Application
[174-183]

PRACTICES

Special Requirements and Considerations for Pre-Marketing Registration Testing of CAR-T Cell Therapy Products
[166-173]

Requirements for Lentiviral Vector Production and Quality Control in Cell and Gene Therapy Products
[184-194]

Production and Quality Control of CAR-T Cells
[195-207]

Commercial Production and Quality Control of Mesenchymal Stem/Stromal Cell-Based New Drugs
[208-218]

Development, Application and Quality Control of Hematopoietic Stem Cell Therapy
[219-233]

Tianjin’s Practice of Boosting CGT Products Incubation through GMP Pilot-Scale Platforms of New R&D Institutions
[234-240]

NEW ADVANCES

Advances in Immune Cell Therapy
[51-65]

Research Progress of Mesenchymal Stem/Stromal Cell Therapy Medicinal Product
[66-77]

Discussion on the Druggability of Hematopoietic Stem Cells
[78-98]

Advances in Pluripotent Stem Cell-Based Cell Therapies
[99-115]

Advances in the Druggability and Clinical Translation of Platelets
[116-128]

Extracellular Vesicles as Therapeutic Agents: Progress and Challenges in Translational Research
[129-145]

Progress and Future Trends in Quality Control of Gene Therapy Products
[146-165]

GMP-Grade Plasmid Production and Quality Control: a Standardized Approach from Basic Research to Clinical Application
[174-183]

PRACTICES

Special Requirements and Considerations for Pre-Marketing Registration Testing of CAR-T Cell Therapy Products
[166-173]

Requirements for Lentiviral Vector Production and Quality Control in Cell and Gene Therapy Products
[184-194]

Production and Quality Control of CAR-T Cells
[195-207]

Commercial Production and Quality Control of Mesenchymal Stem/Stromal Cell-Based New Drugs
[208-218]

Development, Application and Quality Control of Hematopoietic Stem Cell Therapy
[219-233]

Tianjin’s Practice of Boosting CGT Products Incubation through GMP Pilot-Scale Platforms of New R&D Institutions
[234-240]